King's Board Cashing In On $3.6B Pfizer Deal: Suit
By Evan Weinberger ( October 18, 2010, 11:53 AM EDT) -- King Pharmaceuticals Inc. is facing a putative class action from shareholders who say the company's $3.6 million sale to Pfizer Inc. is a bid to cash in on its strong development pipeline at the expense of investors and should be blocked....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.